Alethine

DRACPC ID  DRACPC0077

Active Ingredients   Alethine

Description  A disulfide agent that stimulates T and B-cell functions and exhibits anti-tumor and immunostimulant activity.

Synonyms  Beta Alethine; Beta-alanyl-cysteamine Disulfide; BetaLT; Betathine; N,N'-(Dithiodiethylene)bis(3-aminopropionamide); Alethine

Type  Small Molecule

Disease  Lymphoma, Multiple myeloma

Classification

  

Amino acid and derivative

Structure Information


Molecular Formula  C10H22N4O2S2

Molecular Weight  294.4

Active Sequence  Not available

Sequence Length  Not available

Modification  Not available

Structure

 

Show IUPAC/InChI/SMILES

IUPAC Name  3-amino-N-[2-[2-(3-aminopropanoylamino)ethyldisulfanyl]ethyl]propanamide

InChI  InChI=1S/C10H22N4O2S2/c11-3-1-9(15)13-5-7-17-18-8-6-14-10(16)2-4-12/h1-8,11-12H2,(H,13,15)(H,14,16)

InChI_Key WELIVEBWRWAGOM-UHFFFAOYSA-N

SMILES  O=C(NCCSSCCNC(CCN)=O)CCN

External Codes


PubChem CID  69532

DrugBank Accession Number  DB05800

NCI Thesaurus Code  C2605  

UNII  LY583605Y8   GSRS

CAS  646-08-2



Drug approval


Drug indication
    Investigated for use/treatment in blood (blood forming organ disorders, unspecified), lymphoma (unspecified), and multiple myeloma.

    The drug is not approved.

ClinicalTrials.gov Identifier Title Condition or disease Phase Purpose
NCT00006466 Phase I/II Study to Assess the Safety and Efficacy of Low Doses of Beta LT in Patients With Myeloma Multiple Myeloma and Plasma Cell Neoplasm; Precancerous Condition Phase 1/2 Treatment
NCT00007839 Phase I/II Study to Assess the Safety and Efficacy of Low Doses of Beta LT in Patients With B-Cell Lymphoma Lymphoma Phase 1/2 Treatment
NCT00041379 Phase I/II Study to Assess the Safety and Efficacy of Low Doses of Beta LT in Patients With Waldenstrom's Macroglobulinemia Lymphoma Phase 1/2 Treatment

    More clinical information is obtained from ClinicalTrials.gov.





DRACP is developed by Dr.Zheng's team.